Literature DB >> 28477460

Bee venom for the treatment of Parkinson's disease: How far is it possible?

Kamal Awad1, Abdelrahman Ibrahim Abushouk2, Ahmed Helal AbdelKarim1, Maged Mohammed1, Ahmed Negida3, Ali S Shalash4.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease, characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta leading to depletion of striatal dopamine and motor symptoms as bradykinesia, resting tremors, rigidity, and postural instability. Current therapeutic strategies for PD are mainly symptomatic and may cause motor complications, such as motor fluctuations and dyskinesia. Therefore, alternative medicine may offer an effective adjuvant treatment for PD. Bee venom therapy (BVT) has long been used as a traditional therapy for several conditions, such as rheumatoid arthritis, asthma, and skin diseases. Experimental and clinical studies showed that BVT could be an effective adjuvant treatment for PD. Several mechanisms were suggested for these findings including the ability of BVT to attenuate neuroinflammation, inhibit apoptosis of dopaminergic neurons, protect against glutamate-induced neurotoxicity, and restore normal dopamine levels in the nigrostriatal pathway. In this article, we reviewed and summarized the literature regarding the potential of BVT for the treatment of PD.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bee venom; Complementary therapies; Dopaminergic neurons; Parkinson's disease

Mesh:

Substances:

Year:  2017        PMID: 28477460     DOI: 10.1016/j.biopha.2017.04.065

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  12 in total

Review 1.  Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases.

Authors:  Jessica M de Souza; Bruno D C Goncalves; Marcus V Gomez; Luciene B Vieira; Fabiola M Ribeiro
Journal:  Front Pharmacol       Date:  2018-02-23       Impact factor: 5.810

2.  Animal protein toxins: origins and therapeutic applications.

Authors:  Na Chen; Siqi Xu; Yuhan Zhang; Feng Wang
Journal:  Biophys Rep       Date:  2018-10-11

3.  Comparison of the Protective Effects of Bee Venom Extracts with Varying PLA2 Compositions in a Mouse Model of Parkinson's Disease.

Authors:  Kyung Hwa Kim; Minhwan Kim; Jaehwan Lee; Hat Nim Jeon; Se Hyun Kim; Hyunsu Bae
Journal:  Toxins (Basel)       Date:  2019-06-19       Impact factor: 4.546

4.  Bee venom attenuates neurodegeneration and motor impairment and modulates the response to L-dopa or rasagiline in a mice model of Parkinson's disease.

Authors:  Hanaa Mm Badawi; Rania M Abdelsalam; Omar Me Abdel-Salam; Eman R Youness; Nermeen M Shaffie; Ezz-El Din S Eldenshary
Journal:  Iran J Basic Med Sci       Date:  2020-12       Impact factor: 2.699

Review 5.  Antioxidant Activity in Bee Products: A Review.

Authors:  Marianna Martinello; Franco Mutinelli
Journal:  Antioxidants (Basel)       Date:  2021-01-07

Review 6.  Venoms as an adjunctive therapy for Parkinson's disease: where are we now and where are we going?

Authors:  Parisa Gazerani
Journal:  Future Sci OA       Date:  2020-11-30

7.  Acupuncture-Related Therapies for Parkinson's Disease: A Meta-Analysis and Qualitative Review.

Authors:  Xiaopeng Wen; Kunbin Li; Hao Wen; Qian Wang; Zhiyuan Wu; Xianli Yao; Bing Jiao; Pingge Sun; Shuqi Ge; Chenyang Wen; Liming Lu
Journal:  Front Aging Neurosci       Date:  2021-07-01       Impact factor: 5.750

8.  Clinical Applications of Bee Venom Acupoint Injection.

Authors:  Ting-Yen Lin; Ching-Liang Hsieh
Journal:  Toxins (Basel)       Date:  2020-09-27       Impact factor: 4.546

Review 9.  Apitherapy for Parkinson's Disease: A Focus on the Effects of Propolis and Royal Jelly.

Authors:  Amira Mohammed Ali; Hiroshi Kunugi
Journal:  Oxid Med Cell Longev       Date:  2020-10-17       Impact factor: 6.543

Review 10.  Pharmacoacupuncture for Idiopathic Parkinson's Disease: A Systematic Review of Randomized Controlled Trials.

Authors:  Ki-Ho Cho; Tae-Hun Kim; Woo-Sang Jung; Sang-Kwan Moon; Chang-Nam Ko; Seung-Yeon Cho; Chan-Yong Jeon; Tae Young Choi; Myeong Soo Lee; Sang-Ho Lee; Eun Kyoung Chung; Seungwon Kwon
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-25       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.